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The noncytotoxic soluble factor produced by CD8 T cells inhibits replication of HIV and SIV in vitro and is thought to play
a crucial role in combatting infection in vivo. We determined the effect of human CD8 lymphocytes on the in vitro replication
potential of both wild-type and nef-defective mutants of the simian immunodeficiency virus SIVmac251. Although replication
of wild-type SIVmac251 in unstimulated human PBMC supplemented with IL-2 was unaffected by the presence of CD8 T
cells, the nef mutants were susceptible to the inhibitory effects. The effect of exogenous IL-2 depended upon the culture
conditions: (i) in nonstimulated human PBMC depleted of CD8 T cells, addition of IL-2 had a positive effect on the growth
of the nef-defective viruses; (ii) in total human PBMC, IL-2 appeared to reinforce the CD8 T-cell-dependent inhibition of the
same mutant viruses. This strongly suggests that IL-2 stimulates the noncytotoxic anti-HIV/SIV response of CD8 cells
present in PBMC cultures. PHA stimulation of unfractionated human PBMC overrode the suppression of viral replication by
CD8 T cells. Depletion of activated T cells expressing the IL-2 receptor -chain (CD25 T cells), present in small amounts
in these primary T cell cultures, dramatically reduced viral replication, indicating that the depleted cell population harbors the
target cells permissive for viral replication. Furthermore, using neutralizing antibodies we could show that inhibition by the
-chemokines MIP-1, MIP-1, and RANTES and the inhibitory effect of CD8 lymphocytes on nefmutant SIVmac viruses aresing acINTRODUCTION
Human (HIV) and simian (SIV) immunodeficiency vi-
ruses carry genes encoding Nef, a conserved cytoplas-
mic protein of 25 to 36 kD, which associates with the
plasma membrane through an N-terminal myristate
(Franchini et al., 1986; Kaminchik et al., 1991; Myers et al.,
1993). Nef is expressed as an early protein from abun-
dant, multiply spliced viral mRNA (Klotman et al., 1991).
Several groups have shown that Nef has a positive effect
on viral replication in peripheral blood mononuclear cells
(PBMC) (Terwilliger et al., 1991; DeRonde et al., 1992;
Zazopoulos and Haseltine, 1993) and macrophages
(Murphy et al., 1993; Miller et al., 1994). This enhance-
ment of replication appears to reflect, at least partly, an
increase in the intrinsic infectivity of virus particles
(Chowers et al., 1994; Aiken and Trono, 1995; Miller et al.,
1995; Schwartz et al., 1995) through stimulation of provi-
ral DNA synthesis (Aiken and Trono, 1995; Schwartz et
al., 1995). Furthermore, Nef alters several cellular func-
tions. It downregulates the surface expression of CD4
(Garcia and Miller, 1991; Aiken et al., 1994; Rhee and
Marsh, 1994; Sanfridson et al., 1994) and major histocom-
1209patibility complex class I molecules (Schwartz et al.,
1996). Nef also seems to modulate T cell activation
events in the host cell (Luria et al., 1991; Niederman et
al., 1992; Skowronski et al., 1993; Baur et al., 1994; Spina
et al., 1994; Du et al., 1995).
The importance of Nef is clearly shown by the fact that
functional SIV nef expression is required to maintain high
viral loads in infected rhesus macaques (Kestler et al.,
1991) and by the rapid reversion of point mutations in the
nef gene in vivo (Whatmore et al., 1995). Although ma-
caques immunized with SIV carrying extensive deletions
in the nef gene (SIVnef) are usually fully protected from
infection with the pathogenic wild-type (wt) virus (Kestler
et al., 1991), infection with these forms of live attenuated
vaccine virus can lead to high levels of viremia and
disease progression in both infant and adult macaques
(Baba et al., 1995, 1999; Connor et al., 1998). In addition,
although a cohort of humans infected with a naturally
occurring nef-deletion variant of HIV-1 maintained low
virus loads and remained healthy for at least 14 years
(Deacon et al., 1995), it has recently been reported that
some of these patients are meanwhile showing signs of
CD4 cell loss (Learmont et al., 1999).
The mechanisms controlling virus replication in the
host are unknown. Depletion of CD8 T cells in rhesus
infected with SIVnef is associated with a 1–2 log in-harbored on different levels. © 2002 Elsevier Science (USA)
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ing that these cells play an important role in controlling
viral replication. Two types of CD8 T-cell-mediated an-
tiviral functions have been described in HIV infection:
one involves the classical antigen-specific HLA-re-
stricted cytolysis of infected cells (Walker and Plata,
1990), and the second inhibits HIV replication in the
absence of cell killing (Wiviott et al., 1990; Walker et al.,
1991; Levy et al., 1996). This noncytolytic antiviral re-
sponse was first identified in vitro with lymphocytes from
HIV-seropositive patients (Walker et al., 1986) and corre-
lates with the clinical state of the infected individual
(Mackewicz et al., 1991). The noncytotoxic antiviral activ-
ity is mediated primarily by activated CD28 CD8 cells
(Landay et al., 1993; Barker et al., 1997), which are not
restricted by major histocompatibility complex (MHC)
class I. They are active against a wide variety of HIV
strains, can suppress HIV replication in both CD4 cells
and macrophages (Barker et al., 1998), and are associ-
ated with the production of soluble CD8 cell antiviral
factor (Levy et al., 1996). CD8 T cells secrete potent
antiviral factors able to suppress HIV/SIV replication in
vitro (Chen et al., 1993; Levy, 1993; Ennen et al., 1994;
Baier et al., 1995; Cocchi et al., 1995; Mackewicz et al.,
1995; Blackbourn et al., 1997), which may play an impor-
tant role in controlling the virus in vivo (Cocchi et al.,
1996). However, neutralization of these factors by anti-
bodies does not totally abrogate the antiviral effect of
CD8 cell supernatant, which suggests that the com-
plete repertoire of antiviral factors still remains unknown
(Clerici et al., 1996; Moriuchi et al., 1996).
Considering the negative influence of CD8 cell-me-
diated antiviral activity and the positive influence of Nef,
we examined the interaction of those two. The replica-
tion behavior of the SIVmac251 molecular clone BK28,
carrying a complete nef open reading frame, and a se-
ries of corresponding mutants defective in nef was in-
vestigated under various conditions in unfractionated
and CD8 T-cell-depleted human PBMC. Since blood
from rhesus macaques was not available in sufficient
amounts and sequence analyses have revealed that SIV-
mac shows a 99% homology to HIV-2 (Chakrabarti et al.,
1987), suggesting a common origin (Gao et al., 1992;
Mansfield et al., 1995), blood from healthy human
donors was used. As the Nef protein influences the
activation state of the host cell (Skowronski et al.,
1993; Du et al., 1995), the experiments were, in addi-
tion, performed using primary human T cells in differ-
ent states of activation.
RESULTS
SIVmac251-BK28 nef alleles
Starting with the molecular clone BK28 of SIVmac251,
nef-defective mutants were generated by PCR assembly
(Figs. 1A and 1B; Table 1). BK28nef20 has a single nu-
cleotide exchange at position 9120 (TTG to TAG) result-
ing in a truncated Nef protein of 20 amino acids.
BK28nef56 contains a G to T transversion at position
9227 to give a stop codon (TGA) resulting in a trun-
cated (56 amino acids) Nef protein. BK28nef1 and
FIG. 1. (A) SIVmac251-BK28 nef alleles. A premature stop codon is located in the env gene at position 8785. (B) SIVmac251-BK28 mutant Nef
proteins.
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nef13 carry deletions in the nef gene that neither
overlap with env nor affect the polypurine tract imme-
diately adjacent to the U3 region of the 5 long termi-
nal repeat. They were initially constructed to be tested
as live vaccines in rhesus macaques. The nucleotide
sequence of all mutated nef genes was confirmed by
DNA sequencing. The molecular weights of the Nef
proteins were checked by SDS–PAGE of immunopre-
cipitated, radioactively labeled proteins expressed in
infected HuT78 cells. While the 247-amino acid (aa)
Nef protein of the wild type could be detected, this
36-kDa protein was not detected in cells infected with
the mutants nef20, nef56, and nef13 (data not shown).
The 180-aa Nef protein of mutant nef1 could be
detected (data not shown).
SIVmac251 viruses with defective nef genes show
increased susceptibility to the noncytotoxic antiviral
activity of CD8 lymphocytes
To study the effect of CD8 lymphocytes on the in
vitro replication potential of wild-type and nef-defec-
tive viruses, unfractionated and CD8 T-cell-depleted
PBMC of a healthy blood donor were infected with
SIVmac251-wt and nef mutant viruses BK28nef56,
BK28nef1, and BK28nef13 and cultured in the ab-
sence of IL-2 and exogenous stimulation (Fig. 2). The
replication kinetics were followed for 28 days, and
twice a week cell-free cell culture supernatant was
removed for live virus determination. Full-length wild-
type SIVmac251 replicated with similar kinetics in both
cell populations. However, all nef-defective viruses,
with the exception of the substitution mutant SIV-
mac251-nef56, replicated significantly better in CD8
T-cell-depleted human PBMC than in unfractionated
human PBMC. The defects in the nef gene products
therefore appear to render the virus susceptible to the
negative influence of human CD8 T cells under these
culture conditions. In the absence of IL-2, SIVmac251-
nef56 replicated similarly in complete and CD8 T-cell-
depleted human PBMC, albeit with reduced efficiency
compared to those mutants with deletions in the nef
gene.
IL-2 stimulates the noncytotoxic anti-HIV/SIV
response of CD8 T cells
Simultaneously, the replication kinetics of the
BK28-wt virus, carrying the complete nef open reading
frame, and mutant viruses BK28nef56, BK28nef1, and
BK28nef13 were compared on both unfractionated
and CD8 T-cell-depleted human PBMC in the pres-
ence of IL-2 (Fig. 3). Under these conditions the rep-
lication kinetics of all viruses in CD8 T-cell-depleted
PBMC were accelerated, with virus loads peaking at
day 12 postinfection. In the absence of IL-2, virus
TABLE 1
Mutations Introduced into the SIVmac251-BK28 nef Gene
Mutant Deletion
Nucleotide
exchange
Frame
shift
aa before
frame shift
aa after
frame shift
Length of
Nef
BK28-wt — — — — — 247 aa
BK28-nef20 — 9120 (T A) — — — 20 aa
BK28-nef56 — 9227 (G T) — — — 56 aa
BK28-nef1 9226–9427 — 0 56 124 180 aa
BK28-nef13 9226–9368 — 1 55 (1)a 33 55 aa
a Additional amino acid introduced due to the position of the deletion.
FIG. 2. Replication kinetics of SIVmac251-BK28-wt and nef mutant
viruses in unstimulated, unfractionated versus CD8 T-cell-depleted
human PBMC in the absence of IL-2. Unfractionated (2  107) and
CD8 T-cell-depleted (1.8  107) human PBMC (both unstimulated)
were infected with 2000 TCID50 of the viruses BK28-wt, BK28nef56,
BK28nef1, and BK28nef13. After washing, the cells were resus-
pended in 10 ml medium and cultured for 28 days in the absence of
IL-2. Starting at 7 days postinfection, aliquots of the supernatant were
removed twice weekly for determination of live virus titer. The results
from one representative experiment are shown. The experiments were
repeated three times using PBMC from different donors, with similar
results.
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loads reached similar levels, but with slower kinetics
(Fig. 2). However, whereas the wild-type virus repli-
cated in unfractionated human PBMC to similar levels
regardless of the presence or absence of IL-2 (Figs. 2
and 3), all nef-defective BK28 virus mutants replicated
very poorly in the presence of IL-2. In particular, the
replication of substitution mutant SIVmac251-nef56,
similar in whole and CD8 T-cell-depleted PBMC cul-
tures without IL-2 (Fig. 2), was severely inhibited in
cultures of total PBMC in the presence of IL-2 (Fig. 3).
The negative effect of CD8 T cells on the replication
of nef-defective viruses in unfractionated human
PBMC without exogenous IL-2 (Fig. 2) was even more
pronounced in the presence of IL-2 (Fig. 3). It would
therefore appear that IL-2 stimulates the anti-HIV/SIV
activity of the CD8 T cells in such cultures. It should
be noted that the presence of IL-2 in the culture
medium of unstimulated human PBMC, either total or
CD8 T cell depleted, resulted in an increase in the
number of viable cells by a factor two or more (Fig. 4).
It should be noted that although the increased sus-
ceptibility to the noncytotoxic antiviral activity of CD8
lymphocytes was observed on three different occa-
sions using PBMC from random, unrelated blood do-
nors, the effect occasionally was not observed. There
were cases in which we could not detect a significant
difference between the replication potentials of nef-
defective viruses on total and CD8 T-cell-depleted
PBMC cultures, possibly due to differences in CD8
factor production by (or in vivo activation status of) the
cells. In other cases, even the wild-type virus repli-
cated better in CD8 T-cell-depleted PBMC cultures
than in total PBMC cultures.
PHA stimulation of unfractionated human PBMC
overrides the suppression of viral replication by CD8
T cells
Unfractionated and CD8 T-cell-depleted human
PBMC from the same donor were stimulated with phyto-
hemagglutinin (PHA) for 3 days in the presence of exog-
enous IL-2 and then infected with BK28-wt virus carrying
the complete nef open reading frame and mutant viruses
BK28nef56, BK28nef1, and BK28nef13. All viruses
grew well on both unfractionated and CD8 T-cell-de-
pleted human PBMC (Fig. 5). PHA stimulation of the
unfractionated human PBMC therefore appears to over-
ride the suppression of the viral replication mediated by
CD8 T cells.
Target cells for viral replication in experimentally
nonstimulated human PBMC cultures
SIVmac251-BK28-wt virus replicates in experimentally
unstimulated primary T cells (total or CD8 T cell de-
FIG. 3. Replication kinetics of SIVmac251-BK28-wt and nef mutant
viruses in experimentally unstimulated human total and CD8 cell-
depleted PBMC in the presence of IL-2. Total (2  107) and CD8
cell-depleted (1.8  107) human PBMC (both experimentally unstimu-
lated) were infected with 2000 TCID50 of the viruses BK28-wt,
BK28nef56, BK28nef1, and BK28nef13. After washing, the cells were
resuspended in 10 ml PBMC medium and cultured for 28 days in the
presence of 80 U/ml IL-2. Starting at 7 days postinfection, aliquots of
the supernatant were removed twice weekly for determination of live
virus titer. The results from one representative experiment are shown.
The experiments were repeated three times using PBMC from different
donors, with similar results.
FIG. 4. Effects of IL-2 on viable cell numbers. Unfractionated and
CD8 T-cell-depleted human PBMC (both unstimulated) were cultured
in the presence and absence of IL-2 and infected with SIVmac251-
BK28-wt and nef mutant viruses BK28nef56, BK28nef1, and
BK28nef13. Cell viabilities were determined at different times using
trypan blue staining. The results from one representative experiment
are shown. The experiments were repeated three times using PBMC
from different donors, with similar results.
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pleted; Figs. 2 and 3). Does the BK28-wt Nef protein act
as an activator of lymphocytes and hence of viral repli-
cation? While most lymphocytes in the blood are resting
or minimally activated, HIV and SIV both require acti-
vated CD4 T cells for replication (McDougal et al., 1985),
the one clear exception being the acutely lethal pbj14
strain of SIV (Fultz, 1991). Activated CD4 and CD8 T
lymphocytes express high-affinity IL-2 receptors (Wald-
mann, 1993), which can be detected using antibodies
specific for the -chain (CD25). By magnetic-activated
cell sorting, three cell populations were prepared: (i)
CD8 T-cell-depleted PBMC, (ii) CD8/CD25 T-cell-de-
pleted PBMC, and (iii) CD8 T-cell-depleted/CD25 T-
cell-enriched PBMC. These cells were infected with wild-
type SIVmac251-BK28 virus without prior stimulation.
BK28-wt virus replicated well both in CD8 T-cell-de-
pleted human PBMC and in CD8 T-cell-depleted/CD25
T-cell-enriched human PBMC, but very poorly in PBMC
depleted of both CD8 and CD25 T cells (Fig. 6). This
confirms that prestimulated CD4 lymphocytes (CD4
CD25) harbor the target cells for virus propagation.
Note that in the absence of exogenous IL-2 the viability
of both the uninfected and infected CD8 CD25 cell-
depleted human PBMC populations dropped rapidly
compared to that in the other cultures (Fig. 7, panels C
and D), apparently because this culture is deprived of
almost all of its activated (CD25) cells that have the
potential to expand in the presence of IL-2. This culture
has two handicaps: missing CD25 cells and the ab-
sence of IL-2.
FIG. 5. Replication kinetics of SIVmac251-BK28-wt and nef mutant
viruses in PHA stimulated human total versus CD8 cell-depleted
PBMC in the presence of IL-2. Total (2  107) and CD8 cell-depleted
(1.8  107) human PBMC (both stimulated for 3 days with PHA) were
infected with 2000 TCID50 of the viruses BK28-wt, BK28nef56,
BK28nef1, and BK28nef13. After washing, the cells were resus-
pended in 10 ml PBMC medium and cultured for 28 days in the
presence of 80 U/ml IL-2. Starting at 4 days postinfection, aliquots of
the supernatant were removed twice weekly for determination of live
virus titer. The results from one representative experiment are shown.
The experiments were repeated three times using PBMC from different
donors, with similar results.
FIG. 6. Replication kinetics of SIVmac251-BK28-wt in CD8 T-cell-
depleted, in CD8 CD25 T-cell-depleted, and in CD8 T-cell-depleted/
CD25 T-cell-enriched non-mitogen-stimulated human PBMC. Approx-
imately 1 107 each of CD8 T-cell-depleted, CD8 CD25 T-cell-
depleted, and CD8 T-cell-depleted/CD25 T-cell-enriched non-
mitogen-stimulated human PBMC were infected with 2000 TCID50
SIVmac251-BK28-wt, resuspended in 5 ml PBMC medium, and cultured
for 23 days in the absence of IL-2. Starting at 2 days postinfection,
aliquots of the supernatant were removed twice weekly for determina-
tion of live virus titer.
FIG. 7. Viable cell numbers and percentages of activated (CD25)
CD4 T cells in cultures of CD8 T-cell-depleted, CD8 CD25 T-cell-
depleted, and CD8 T-cell-depleted/CD25 T-cell-enriched unstimu-
lated human PBMC infected with SIVmac251-BK28-wt. CD8 T-cell-
depleted (A, B), CD8 CD25 T-cell-depleted (C, D), and CD8 T-cell-
depleted/CD25 T-cell-enriched (E, F) unstimulated human PBMC were
mock infected (A, C, E) or infected with 2500 TCID50 SIVmac251-BK28
(B, D, F). After washing, cells were resuspended in 5 ml medium and
cultured for 23 days in the absence of IL-2. Starting at 2 days postin-
fection, aliquots of the supernatant were removed twice weekly. Viable
cell numbers were determined by trypan blue staining, and cells were
prepared for cell surface CD4 CD25 FACS analysis as described
under Materials and Methods.
213nef-DEFECTIVE SIV AND CD8 LYMPHOCYTES
Increase of activated CD4 T cells in human PBMC
cultures
FACS analysis of freshly isolated PBMC revealed com-
parable amounts of CD4 CD25 in the total (3%; abso-
lute number, 6  105) and in the CD8 T-cell-depleted
cultures (3.9%; absolute number, 7  105) in the gated
lymphocyte populations. Using FACS analysis we deter-
mined an increase of activated (CD25) CD4 T cells in
unfractionated and CD8 T-cell-depleted PBMC cultures
in the presence and absence of exogenous IL-2 through-
out the course of the experiment (Fig. 8), demonstrating
comparable amounts of potential target cells in the cor-
responding total and fractionated PBMC cell culture sys-
tems.
Increase of activated CD8 T cells in human PBMC
cultures
Using FACS analyses we determined the increase of
activated CD8 T cells in unfractionated and CD8
T-cell-depleted human PBMC cultures in the presence
and absence of exogenous IL-2 throughout the course
of the experiment (Fig. 9). CD8 T cell depletion re-
sulted in a 20-fold decrease in the number of cells
expressing high levels of this surface molecule. In
unfractionated PBMC cultures the presence of IL-2 led
to a significant increase in activated CD8 T cells
(Fig. 9).
Effect of the -chemokines MIP-1, MIP-1, and
RANTES and of IL-16 on the replication of
SIVmac251-BK28-wt virus and nef mutant BK28nef20
in total human PBMC
We next determined the effect of known antiviral ef-
fectors derived from CD8 T cells on the replication
potential of BK28-wt virus and nefmutant BK28nef20 (Fig.
10). Total PBMC were infected with BK28-wt and nef
mutant BK28nef20 in the presence of a cocktail of neu-
tralizing antibodies against the -chemokines MIP-1,
MIP-1, and RANTES (Cocchi et al., 1995, 1996) and
IL-16, respectively. The presence of neutralizing antibod-
ies against IL-16 had no significant effect on the replica-
tion kinetics of either the BK28-wt virus or the BK28nef20
virus (Fig. 10). The presence of neutralizing antibodies
against the -chemokines MIP-1, MIP-1, and RANTES
increased the replicative capacity of both the BK28-wt
virus and the nef mutant BK28nef20 tremendously (Fig.
10), suggesting that the inhibition of viral replication by
-chemokines and the inhibitory effect of CD8 lympho-
cytes on nef mutant SIVmac viruses are harbored on
different levels.
DISCUSSION
Nef and the activation state of the target cells
permissive for viral replication
We studied the effect of the CD8 cell-derived HIV/SIV-
suppressing activity on wild-type and nef mutant viruses
in an in vitro replication system. SIVmacBK28-wt virus
could replicate well in PBMC cultures which had not
FIG. 8. Kinetics of activated (CD25) CD4 T cells in human PBMC
cultures. Total and CD8 T-cell-depleted human PBMC were cultured
for 28 days in the presence and absence of IL-2. At 1, 7, and 14 days
postisolation, aliquots of the cell cultures were removed and cells were
prepared for cell surface CD4 CD25 FACS analysis as described
under Materials and Methods.
FIG. 9. Kinetics of activated (CD25) CD8 T cells in human PBMC
cultures. Total and CD8 T-cell-depleted human PBMC were cultured
for 28 days in the presence and absence of IL-2. At 1, 7, 14, 21, and 28
days postisolation, aliquots of the cell cultures were removed and cells
were prepared for cell surface CD8 CD25 FACS analysis as de-
scribed under Materials and Methods.
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been experimentally stimulated with mitogen. While co-
receptor expression (CCR5 in the case of SIVmac251;
Chakerian et al., 1997) is required for viral entry into
CD4 cells, productive infection requires cellular activa-
tion and entry into the G1b phase of the cell cycle (Zack
et al., 1990; Korin and Zack, 1998). Therefore, replication
of HIV/SIV occurred, at least initially, in cells naturally
activated in vivo before removal from the body and thus
resembling the physiologic situation in vivo. Approxi-
mately the same amounts of activated (CD25) CD4
cells were detected in the unfractionated and CD8
T-cell-depleted cell cultures, indicating that comparable
numbers of target cells permissive for SIV replication
were present in both culture systems.
It has been postulated that the major function of Nef is
to stimulate resting cells after infection to allow virus
propagation. This idea has gained further support by the
observation that the ability of the acutely pathogenic
SIVpbj14 to activate and grow in unstimulated PBMC
cultures is due to the presence of a second YXXL motif in
Nef with the characteristics of an SH2 binding domain
(Fultz, 1991; Du et al., 1995). Indeed, site-directed mu-
tagenesis of SIVmac239 nef to yield a second YXXL motif
was sufficient to impart the pbj14 phenotype both in vitro
and in vivo (Du et al., 1995). We have shown here that
SIVmac-BK28 is able to replicate well in PBMC in the
absence of exogenous mitogen or IL-2 and that defects
in Nef reduce this capability. On the face of it, this would
seem to support a stimulatory role for Nef. However,
removal of CD25 cells from cultures of CD8 T-cell-
depleted PBMC virtually prevented replication of the
wild-type virus in the absence of exogenous IL-2 (Fig. 6).
Furthermore, cytokine signals seem to be sufficient for
HIV infection of resting T lymphocytes, since resting cells
stimulated with the cytokine IL-2, IL-4, IL-7, or IL-15 could
be infected with a replication-competent CCR5 tropic
HIV-1 (Unutmaz et al., 1999), albeit with a low efficiency.
The presence of an intact BK28 Nef is insufficient to
permit replication in truly resting T cells. In this context,
it is important to note that the suppressive effect of CD8
T cells was not observed with PHA-stimulated unfrac-
tionated human PBMC (Fig. 5). The experimental finding
that PHA stimulation of unfractionated human PBMC
overrides the suppression of viral replication by CD8 T
cells seems to be in contrast to the fact that PHA is
known to activate this antiviral activity. Doubtlessly, PHA
stimulation provides a large reservoir of activated target
cells. But, since there is a role of Nef in modulating T cell
activation events in the target cell, one could speculate
that stimulation by PHA renders the stimulated cell with
no nef function needed (wt and nef mutant viruses do not
behave differently). Indeed, experimental evidence sug-
gests that Nef can promote T cell activation (Baur et al.,
1994; Du et al., 1995; Alexander et al., 1997; Hanna et al.,
1998). Recently, it has been reported that HIV-1 Nef
increases T cell activation in a stimulus-dependent man-
ner (Schrager and Marsh, 1999). It has to be noted that
activation of T cells, as defined by IL-2 generation, stim-
ulated with classical chemical mitogens was unaffected
by the expression of Nef (Schrager and Marsh, 1999).
However, Nef increased IL-2 secretion when cells were
stimulated through the T cell receptor and the CD28
coreceptor (Schrager and Marsh, 1999). Studies of HIV
infection of primary cells typically require the use of
mitogens such as PHA. Schrager and Marsh (1999) de-
duced that under these conditions the enhancing activity
of Nef may not be evident. In addition, they showed that
Nef lowers the threshold of the dual-receptor T cell
activation pathways because the increase in activation is
caused by an increase in the number of cells reaching
full activation. Furthermore, Wang et al., (2000) published
that the Nef-mediated induction of IL-2 reflects the acti-
vation of the transcription factors NF-AT and NFB. Very
recently, it was reported that infection with HIV leads to
selective transcription of the tat and nef genes before
integration in quiescent cells, leading to increased T cell
activation (Wu and Marsh, 2001). Artificial stimulation of
PBMC by PHA should be avoided in assays designed to
identify putative antiviral factors.
Control of viral replication in vitro
The data presented here suggest that one positive
effect on viral replication mediated by an intact nef is the
abrogation of the noncytotoxic anti-HIV/SIV activity of
FIG. 10. Replication kinetics of SIVmac251-BK28-wt and nef mutant
BK28nef20 in the presence of neutralizing antibodies against the
-chemokines MIP-1, MIP-1, and RANTES and IL-16. Total human
PBMC (2  106) were incubated in the presence of a cocktail of
neutralizing antibodies against -chemokines MIP-1, MIP-1, and
RANTES for 2 h. The same amount of total human PBMC was incubated
in the presence of a neutralizing antibody against IL-16. After a prein-
cubation time of 2 h, cells were infected with 500 TCID50 of SIVmac251-
BK28-wt and nef mutant virus BK28nef20. After washing, the cells were
resuspended at a cell density of 2 106 cells/ml in PBMC medium and
cultured for 28 days in the presence of neutralizing antibodies against
the -chemokines MIP-1, MIP-1, and RANTES and IL-16 and in the
presence of 80 U/ml IL-2. Starting at 4 days postinfection, aliquots of
the supernatant were removed twice weekly for determination of the
amount of viral p27 gag protein. The results from one representative
experiment are shown. The experiments were repeated twice using
PBMC from different donors, with similar results.
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CD8 T cells. The replication of SIVmac251-BK28 mu-
tants expressing defective nef gene products was found
to be suppressed by human CD8 T cells, whereas the
full-length virus was not. Under the conditions used, the
Nef protein of SIVmac251-BK28 seemed to counteract
the anti-HIV/SIV activity of CD8 T cells. This effect was
accentuated in unstimulated, unfractionated human
PBMC by the addition of exogenous IL-2, which therefore
appears to stimulate the antiviral effect of CD8 T cells.
This is in agreement with data showing IL-2 induction of
CD8 T-cell-mediated suppression of HIV replication in
CD4 T cells and a corresponding abrogation of the
stimulatory effect of this cytokine on virus expression
(Kinter et al., 1995). The presence of exogenous IL-2
induced a quantitative increase in activated CD8 cells,
particularly in the unfractionated PBMC cultures (Fig. 9).
Besides this, IL-2 appears to induce a qualitative in-
crease in the HIV-1-suppressing activity of activated
(CD25) CD8 cell populations (Kinter et al., 1995).
Effect of chemokines
Primate lentiviruses use chemokine receptors in addi-
tion to the CD4 receptor to initiate virus infection. SIV
uses CCR5 as coreceptor (Chackerian et al., 1997), and
the native ligands for CCR5, the -chemokines MIP-1,
MIP-1, and RANTES, specifically inhibit infection of SIV.
The mechanism of HIV/SIV inhibition by chemokines is
complex. In addition to blocking viral entry by competi-
tion for receptor occupancy, downregulation of corecep-
tors as a result of chemokine binding reduces the effi-
ciency of viral entry (Trkola et al., 1998). Furthermore,
signals transduced into the cell by the receptor interac-
tions of chemokines might interfere with transcription of
the viral genome (Littman, 1998).
The presence of neutralizing antibodies against the
-chemokines in our replication kinetics (infection of
CD8 T-cell-depleted PBMC with SIVmac-BK28 and SIV-
mac-nef20) had tremendous effects on the replication
potential of both wild-type and nef mutant virus. If the
-chemokines MIP-1, MIP-1, and RANTES would
merely be responsible for the increased susceptibility of
the nef-defective SIVmac virus mutants to the noncyto-
toxic antiviral activity of CD8 lymphocytes, the presence
of neutralizing antibodies against these -chemokines
would increase the replication potential of the nef mu-
tants up to the levels detected in CD8-depleted PBMC
cultures. But what we see is a tremendous augmentation
of the replicative capacity of both the BK28-wt virus and
the nef mutant BK28nef20 in the presence of neutralizing
antibodies against the -chemokines. We conclude that
these two effects (inhibition by -chemokines and the
inhibitory effect of CD8 lymphocytes on nef mutant
SIVmac viruses) are harbored on different levels. Further-
more, it has been reported that expression of the core-
ceptor CCR5 on T cells is upregulated by exposure to
IL-2 in vitro (Trkola et al., 1996; Bleul et al., 1997) and in
vivo (Zou et al., 1999).
Control of viral replication in vivo
The observation that rhesus macaques infected with
SIVmac carrying large deletions in the nef gene show
lower virus loads than wild-type infected animals (Kestler
et al., 1991) and the finding that depletion of CD8 cells
in such animals leads to a dramatic increase in plasma
viremia (Metzner et al., 2000) suggest that CD8 cells
play an important role in controlling viral replication.
Inhibition of SIV replication by CD8 T cells from animals
immunized with live attenuated SIV strains involves both
MHC-restricted and MHC-unrestricted mechanisms, and
the latter is due principally to soluble factors other than
RANTES, MIP-1, and MIP-1 (Gauduin et al., 1998).
There is evidence that cytotoxic T lymphocytes (CTLs)
are critical in controlling virus replication. Low viral loads
in HIV-1-infected long-term nonprogressors (Cao et al.,
1995; Dyer et al., 1999) and in rhesus macaques infected
with SIVnef viruses (Johnson et al., 1997) have been
associated with high levels of virus-specific CTL activity.
Recently, evidence for the in vivo control of wild-type SIV
replication during acute and chronic infection has been
obtained (Jin et al., 1999; Schmitz et al., 1999).
In vivo, Nef may confer a growth advantage to the virus
by downregulating class I MHC (Schwartz et al., 1996)
and thereby enabling infected cells to avoid CTL killing
(Collins et al., 1998). As a consequence of this, nef-
defective viruses would be more susceptible to lysis by
CTL. Refering to our own data, nef-defective viruses are
more susceptible to the antiviral activity of CD8 cells in
vitro, and if this is also the case in vivo it could account
for the suppressed virus loads seen in SIVmacnef-
infected animals.
Why do SIVmac251-BK28 nef mutant viruses show
increased susceptibility to the noncytotoxic antiviral
activity of CD8 lymphocytes?
The molecular mechanism underlying our observation
that defects in the nef gene render primate lentiviruses
more susceptible to the noncytotoxic antiviral activity of
CD8 lymphocytes remains to be elucidated. To answer
the question of whether a soluble factor is involved, we
performed experiments with a double-chamber system,
providing CD8 T cells separated by a membrane from
the CD8 T-cell-depleted PBMC culture (data not
shown). We did not see a significant difference between
the replication of the nef-defective viruses in the CD8
T-cell-depleted PBMC culture and that in the double-
chamber system. Replication in unfractionated PBMC
was hampered. Our interpretation of this result is that the
functioning of a soluble factor(s) cannot be ruled out.
Maybe close cell–cell contact is necessary to allow func-
tion of a soluble factor(s).
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The increased susceptibility of nef mutants to the
antiviral effects of CD8 T cells, while being a new
observation, could be the result of the previously de-
scribed Nef functions. One possible explanation (al-
though there is no direct evidence for this hypothesis)
could involve downregulation of the CD4 molecule at the
cell surface by Nef (Garcia and Miller, 1991; Aiken et al.,
1994; Rhee and Marsh, 1994; Sanfridson et al., 1994). All
of the BK28 Nef mutant proteins used in this study lack
this ability (data not shown). Removal of their cell surface
receptors is a common feature of retroviruses and is
usually mediated by the viral Env proteins. In contrast,
Nef induces the internalization and degradation of pre-
existing cell surface CD4 and therefore has the potential
to act far more rapidly, particularly as Nef is an early
protein. As well as hindering superinfection by other
viruses (Benson et al., 1993) and facilitating the release
of virus particles, removal of CD4 would block any anti-
viral signal entering the cell via this molecule. CD4 is
physically associated with the protein tyrosine kinase
p56lck, which supports the notion that this integral mem-
brane glycoprotein participates in signal transduction
(Rudd et al., 1988; Veillette et al., 1989; Weiss and Litt-
man, 1994). Furthermore, cross-linking of cell surface
CD4 by certain monoclonal antibodies has been shown
to inhibit HIV replication in the cell at the level of expres-
sion (Benkirane et al., 1993). As defects in Nef render the
virus more susceptible to the antiviral effect of CD8
cells, it is possible that one effect of an intact Nef is to
abrogate one or more of the CD8 T cell suppressor
factors by the removal of CD4. IL-16, a candidate antiviral
factor secreted by CD8 T cells (Baier et al., 1995, 1997),
is clearly not responsible for the observed effect.
In conclusion, the SIVmac Nef protein was shown to
have the additional function of abrogating the suppres-
sive effect of antiviral factors produced by human CD8
cells. Although derived from an in vitro test system, this
phenomenon, if occurring in vivo, could further explain
the attenuated phenotype of Nef-deletion mutants in ma-
caques. Ongoing experiments using a panel of HIV-1
deletion mutants should allow more light to be shed on
this and the many other functions of nef.
MATERIALS AND METHODS
Construction of SIVmac nef mutants
The biologically active proviral SIVmac251 DNA clone
BK28 (Kornfeld et al., 1987), was kindly provided by J.
Mullins (University of Washington, Seattle, WA) (GenBank
Accession No. X06393). Plasmid pPCRnef-wt, starting at
nucleotide 8724 and comprising the complete 3 end of
the proviral genome, was generated by PCR with BK28
as a template using the primers A8724() 5-CGATGAAT-
TCTCTAGAGCTAGCTAAGTTAAGGCAGGGG-3 corre-
sponding to positions 8724 to 8745 of SIVmac251-BK28
(in bold) and B10250() 5-CGATGAATTCATGCTAGG-
GATTTTCCTGCTTCGG-3 corresponding to positions
10250 to 10227 of SIVmac251-BK28 (in bold). Both contain
an EcoRI restriction endonuclease site (underlined). The
plasmid pPCRnef-wt served as a template for the follow-
ing constructs.
Construction of nef substitution mutants
Substitution nef mutant BK28nef56 was generated by
PCR assembly using two PCR amplified ds fragments
with homologous regions. The homologous region con-
tained a single nucleotide exchange from G to T at
position 9227. Fragment A was amplified using the
primer pair A8724() and A9232() 5-
CTGTCACTCACAAGAGCGTGAGCTCAAG-3, the latter
corresponding to positions 9232–9204 of SIVmac251-
BK28 (the nucleotide exchange at position 9227 is un-
derlined). Fragment B was amplified using primer pair
B9211() 5-CTCACGCTCTTGTGAGTGACAGAAATAC-3,
corresponding to positions 9211–9239 of SIVmac251-
BK28 (the nucleotide exchange at position 9227 is un-
derlined) and B10250(). The PCR fusion product of
fragments A and B using the outer primer pairs A8724()
and B10250() was purified, digested with EcoRI, and
inserted into the EcoRI site of vector pUC18 (pPCRnef56).
The substitution nefmutant BK28nef20 was generated by
PCR assembly. The homologous region contained a sin-
gle nucleotide exchange from T to A at position 9120.
Fragment A was amplified using the primer pair
A8724() and A9125() 5-CCCGCTAGAGTTTCTGT-
CGCAGAT-3, the latter corresponding to positions 9125
to 9101 of SIVmac251-BK28 (the nucleotide exchange at
position 9120 is underlined). Fragment B was amplified
using primer pair B9106() 5-GCGACAGAAACTCTAG-
CGGGCGCGT-3, corresponding to positions 9106–9130
of SIVmac251-BK28 (the nucleotide exchange at position
9120 is underlined) and B10250(). The PCR fusion prod-
uct of fragments A and B using the outer primer pairs
A8724() and B10250() was purified, digested with
EcoRI, and inserted into the EcoRI site of vector pUC18
(pPCRnef20).
Construction of Nef deletion mutants
Nef deletion mutant BK28nef1 was also created
by PCR assembly. Briefly, fragment A was amplified us-
ing primer A8724() and the assembly primer A9446()
5-CCAGTCCCCCCTTTTCTTTTTCACAAGAGCGTGAGC-
TCAAG-3 (SIVmac251-BK28 sequence 9446–9427 is in
bold and 9225–9205 is underlined). Fragment B was
amplified using the assembly primer B9222() 5-GTGA-
AAAAGAAAAGGGGGGACTGGAAGGG-3 (SIVmac251-
BK28 sequence 9222–9225 is in bold and 9427–9451 is
underlined) together with primer B10250(). PCR fusion
of fragments A and B using the outer primer pair
A8724() and B10249(), restriction with EcoRI, and
cloning into the EcoRI site of pUC18 resulted in
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pPCRnef1, which contains a nef gene missing precisely
the sequences between position 9225 and 9427. Con-
struction of the deletion mutant BK28nef13 followed the
same protocol except that the assembly primer A9387()
5-GCTCTTAGGGGAACTTTTGTCACAAGAGCGTGAGCT-
CAAG-3 (SIVmac251-BK28 sequence 9387–9369 is in
bold and 9225–9205 is underlined) was used as the 3
primer for fragment A and primer B9369() 5-
CAAAAGTTCCCCTAAGAGCAATG-3 (SIVmac251-BK28
sequence 9369–9391 is in bold) as the 5 primer for
fragment B. The resulting plasmid pPCRnef13 had the
nef gene sequences from positions 9225 to 9368 deleted.
The molecular weights of the Nef proteins were
checked by SDS–PAGE of immunoprecipitated, radioac-
tively labeled proteins (data not shown).
Transfection and production of virus stocks
SW480 cells [American Type Culture Collection
(ATCC), Rockville, MD] were grown at 37°C in Dulbecco’s
modification of Eagle’s medium supplemented with 10%
(v/v) fetal calf serum (FCS). The different NheI-EcoRI
fragments of the mutated nef genes of BK28 were ligated
to the 15-kb pBK28 NheI-EcoRI vector fragment and used
to transfect subconfluent cultures of SW480 cells using
the LipofectAMINE reagent (Life Technologies, Gaithers-
burg, MD). Two days posttransfection, cultures were
cocultivated with HuT78 cells for 48 h. Infected HuT78
cells were subsequently removed and maintained in
RPMI 1640 supplemented with 10% (v/v) fetal calf serum.
Cell-free culture supernatant from permanently infected
HuT78 cultures was passed through a 0.22-m-pore-size
filter and stored as aliquots in liquid nitrogen. Titration of
the virus stocks was performed by endpoint dilution on
C8166 cells (ATCC).
Quantification of virus infectivity
Virus-containing supernatants were serially diluted in
media and aliquoted (50 l per well, eight replicates per
dilution) into U-well microtiter plates containing 2000
C8166 cells in 150 l. After 7 days incubation at 37°C,
cells and viruses were lysed by the addition of 20 l 2%
Tween 20, and 50 l from each well was transferred to
the corresponding well of an ELISA plate for detection of
the viral Gag protein using a p27 antigen capture assay.
The number of positive wells was then used to determine
the TCID50 of the original sample using the Spearmann–
Karber method.
Viral protein analysis
Permanently infected HuT78 cells were metabolically
labeled with [35S]methionine (30 Ci/ml) for 4 h and lysed
in radioimmunoprecipitation assay (RIPA) buffer [150 mM
NaCl, 5 mM Tris–Cl (pH 7.9), 10 mM EDTA, 1% Triton
X-100, 0.1% SDS, 1% sodium deoxycholate]. Nef proteins
were immunoprecipitated using a rabbit polyclonal Nef-
specific antiserum raised against Escherichia coli-de-
rived BK28 Nef and then subjected to SDS–PAGE.
Cell culture and infections
For each experiment, PBMC were isolated from the
peripheral blood of a seronegative donor by Ficoll–diatri-
coate (Histopaque, Sigma, Deisenhofen, Germany) den-
sity gradient centrifugation and maintained in RPMI 1640
supplemented with 20% FCS, 1 mM glutamine with and
without 80 U/ml recombinant IL-2. Half of the isolated
PBMC were used as unfractionated culture and the other
half were depleted of CD8 T cells using CD8 mi-
crobeads. Both cultures were resuspended in the same
volume of medium, resulting in the same concentration
of potential target cells. For stimulation, cells were cul-
tivated for 1 day in the presence of 18 g/ml PHA,
washed in medium, and further cultivated in the pres-
ence of 80 U/ml IL-2. To study replication kinetics, 2 
107 unfractionated and 1.8  107 CD8 T-cell-depleted
PBMC (with and without PHA stimulation) were infected
with 2000 TCID50 of the different viruses for 4 to 8 h. After
being washed three times in medium, the cells were
cultured for 28 days in the presence or absence of IL-2.
Twice weekly, aliquots of the supernatant were removed
and the titer of infectious virus was assayed immediately
as described above. Cells were refed with fresh medium,
and viable cell numbers were determined by trypan blue
staining.
Infections in the presence of neutralizing antibodies
Unfractionated and CD8 T-cell-depleted PBMC were
prepared as described above and preincubated with
neutralizing antibodies (NAb) against human MIP-1,
MIP-1, and RANTES (R&D Systems, Minneapolis, MN)
for 2 h before the start of the infection. The anti-RANTES
NAb was used at 1.5 g/ml (10-fold excess), the anti-
MIP-1 NAb at 150 g/ml (2-fold excess) and the anti-
MIP-1 NAb at 10 g/ml (10-fold excess). The anti-IL-16
NAb (PharMingen, San Diego, CA) was used at a final
concentration of 10 g/ml (10-fold excess). Levels of
MIP-1, MIP-1, RANTES, and IL-16 in cell supernatants
were measured with enzyme-linked immunosorbent as-
say kits from R&D Systems according to the manufac-
turer’s instructions. Antibody concentrations were main-
tained for the duration of the experiment.
Purification of T lymphocyte subsets
Freshly isolated PBMC from a healthy blood donor
were washed in medium and half were depleted of CD8
T cells using CD8 microbeads (Miltenyi Biotech, Ber-
gisch Gladbach, Germany) following the manufacturer’s
instructions. For CD25 cell depletion, CD8 T-cell-de-
pleted PBMC were incubated at 4°C with an anti-CD25
monoclonal antibody (anti-IL-2R -chain; Becton Dickin
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son, San Jose, CA). After washing, cells were incubated
with biotin-labeled goat antibody specific for mouse IgG
F(ab)2 (Dianova, Hamburg, Germany), washed again,
and incubated with both super-paramagnetic mi-
crobeads conjugated with streptavidin (Miltenyi Biotech)
and microbeads conjugated with goat anti-mouse IgG
(Miltenyi Biotech) to allow possible cross-linking. Mag-
netic-activated cell sorting was then performed accord-
ing to the manufacturer’s instructions.
Cell surface marker analysis
Cells were stained simultaneously with phycoerythrin-
conjugated anti-CD4 (Leu3a, Becton Dickinson) or anti-
CD8 mAb (Leu2a, Becton Dickinson) and fluorescein
isothiocyanate-conjugated anti-CD25 mAb (anti-IL-2Ra,
Becton Dickinson) for 40 min on ice in the dark. Percent-
ages of CD4/CD25- and CD8/CD25-positive T cells were
determined by FACS analysis (FACScan; Becton Dickin-
son, Heidelberg, Germany) of gated lymphocyte popula-
tions.
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